-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Staging Experts Offer Insights on Challenges of Nodal Classification
Adding to the discussion, Drs. David Ball, Daniel Steinfort, and Susan Harden propose alternative approaches for the complex task of improving nodal staging.
-
Mesothelioma Pioneer Delivers 2023 Heine H. Hansen Keynote Lecture
The Netherlands Cancer Institute’s Dr. Paul Baas was honored for his significant contributions to lung cancer research during the 2023 European Lung Cancer Congress.
-
Thoracic Oncologists Divided Regarding Role of Neoadjuvant Chemoimmunotherapy
Consensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC.
-
From the Editors April 12, 2023
ILCN Associate Editors Drs. Suresh Senan and Witold Rzyman add clinical perspective to surveillance frequency discussion.
-
Pragmatic Approach to Trial Design Born from Lung-MAP Substudy
In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients.
-
New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC.
-
ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology
In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field.
-
Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients
Dr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients.
-
Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations
During TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment.
-
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint.